Seattle-based Clinicians on Effective Treatment Combos in EGFR-Mutated NSCLC
A panel of experts met to discuss the best treatment options for patients with EGFR or TP53-mutated non–small cell lung cancer.
Advancement of First-Line Treatments on EGFR-Mutated NSCLC
As part of a Satellite Sessions program focused on the Cleveland Clinic and surrounding institutions, CancerNetwork hosted a panel discussion on treatment options for patients with EGFR-mutated NSCLC.
NSCLC Experts Ponder Best First-Line Treatment Options
The discussion on NSCLC narrowed in on findings from recent clinical trials, particularly involving a combination regimen of amivantamab plus lazertinib vs osimertinib and chemotherapy.
University of Chicago Thought Process on First-line Treatment in EGFR NSCLC
Referring to the NCCN guidelines for the treatment of EGFR-mutated NSCLC will help clinicians determine which treatments are best recommended.
Mayo Clinic on AE Management Strategies for EGFR-Mutated NSCLC
The combination of amivantamab plus lazertinib has emerged as a potential treatment option for patients with EGFR-mutated NSCLC and has shown sufficient efficacy responses.
Leading Scientifically Rigorous Research in Novel Brain Cancer Therapies
Shwetal Mehta, PhD, highlights early phase clinical trials, biomarker testing strategies, and potential next steps for research in the brain cancer field.
OST-HER2 Significantly Prevents Recurrent Lung Metastatic Osteosarcoma
Interim analysis data show improvements in overall survival with OST-HER2 in this osteosarcoma population compared with historical controls.
FDA Approves Dato-DXd in Metastatic HR+/HER2– Breast Cancer
Data from the TROPION-Breast01 trial support the FDA approval of datopotamab deruxtecan for those with metastatic HR–positive, HER2-negative breast cancer.
Acalabrutinib Plus Chemotherapy Provides Cover for High-Risk Patients in MCL
“Some of the early data that came out of the [ECHO] trial that led to this approval does suggest that it may be beneficial in some high-risk patients,” Tycel Phillips, MD, said.
FDA Issues CRL for Tabelecleucel in EBV+ Lymphoproliferative Disease
The CRL did not identify any deficiencies related to the manufacturing, efficacy, or safety outlined in the BLA, and no new clinical trials were requested.
Durvalumab Plus Bevacizumab Improves PFS Outcomes in Unresectable HCC
Phase 3 EMERALD-1 trial results reveal that no new adverse events were identified with durvalumab plus bevacizumab in patients with unresectable HCC.
Brentuximab Vedotin Combination Improves Survival in Pretreated R/R DLBCL
Brentuximab vedotin, lenalidomide, and rituximab yielded a median OS of 13.8 months and a median PFS of 4.2 months in the phase 3 ECHELON-3 trial.
FDA Approves Sotorasib/Panitumumab in KRAS G12C-Mutated CRC
Results from the CodeBreaK 300 trial helped lead to the approval of sotorasib/panitumumab in KRAS G12C-mutated CRC.
FDA Approves Acalabrutinib Combo in Previously Untreated MCL
The FDA has approved acalabrutinib in previously untreated MCL based on results from the phase 3 ECHO trial.
Moving Novel Brain Cancer Treatment Classes Down the Development Pipeline
Shwetal Mehta, PhD, describes efforts regarding the development of protein degraders and antibody-drug conjugates in the neuro-oncology field.
Isatuximab Combo Earns Chinese Approval in R/R Multiple Myeloma
Additionally, the Chinese Society of Clinical Oncology and Chinese Anti-Cancer Association guidelines recommend the isatuximab regimen for this population.
FDA Approves Axatilimab in 9 Mg and 22 Mg Vial Sizes for GVHD
The developers expect the product to be available for order in the United States in early February 2025.
TACE Plus Lenvatinib/Pembrolizumab Boosts PFS in Unresectable Liver Cancer
Adding lenvatinib/pembrolizumab to TACE elicits a numerical overall survival improvement in the LEAP-012 trial, although additional follow-up is necessary.
Evaluating a CNS-Penetrant EGFR Inhibitor in Brain Cancer
Liquid biopsy tests may help determine the extent of activity among patients who receive a novel fourth-generation EGFR inhibitor for brain cancer.
Performing Timely Testing in Novel Brain Cancer Therapy Development
Shwetal Mehta, PhD, highlights novel brain cancer drug development procedures in the clinical lab and pre-clinical arms of the Ivy Brain Tumor Center.
FDA Receives NDA for TAR-200 in BCG-Unresponsive High-Risk NMIBC
Data from the phase 2b SunRISe-1 study support the NDA for TAR-200 in patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer with CIS.
Sasanlimab Plus BCG Boosts Event-Free Survival in High-Risk NMIBC
FDA Clears Investigational New Drug Application for R-5780 in Solid Tumors
The RISE R-5780-01 trial will evaluate the safety and tolerability of R-5780 in patients with melanoma, basal cell carcinoma, or squamous cell carcinoma.
Ponsegromab Reduces Symptoms Linked to Cancer Cachexia, Elevated GDF-15
Patients in the ponsegromab group had significantly greater weight gain and physical activity than those in the placebo arm in a phase 2 trial.
Low ctDNA Levels are Prognostic of Outcomes in Early-Stage Lung Adenocarcinoma
The NeXT Personal platform identified minuscule amounts of ctDNA that were found to be predictive of OS and RFS outcomes in patients with lung adenocarcinoma.
High Immunoglobulin Expression Shows Long-Term Survival in Breast Cancer
Data support the IGG signature, especially its key gene subset, as a potential marker of sustained antitumor activity in breast cancer.
Aggressive End-of-Life Care More Likely in ICD Users with Advanced Cancers
Nearly half of patients with an ICD had a device programming encounter near the end of life, which could present an opportunity to discuss goals of care.
Lete-cel Earns FDA Breakthrough Therapy Designation in Pretreated MRCLS
In the IGNYTE-ESO trial, letetresgene autoleucel elicited an ORR of 43%, a median PFS of 7.7 months, and a median DOR of 12.2 months in those with MRCLS.
AI-Supported Mammography Screening Leads to Increased Breast Cancer Detection Rate
The use of artificial intelligence led to a higher rate of breast cancer detection as an improvement for mammography screening compared with standard detection methods.
Using Biopsies to Inform Response Characteristics in Kidney Cancer
Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.
